On August 11, DUALITYBIO-B rose 5.28% in regular trading, trading at 207.6 HKD/share, with turnover of approximately 106 million HKD. The stock continued its rebound driven by broad-based strength across the biotechnology sector.

The rally was primarily fueled by a collective surge in biotech peers, with BeiGene up 4.41%, Zai Lab up 4.6%, and Akeso up 2.76%, reflecting sustained sector sentiment recovery. DUALITYBIO-B had previously dropped sharply on July 30 due to competitive pressure from GSK in its core ADC pipeline, and has since been gradually stabilizing and recovering.

Supporting the recovery, the company's fundamentals remain underpinned by multiple catalysts: its B7-H3 ADC received NMPA Breakthrough Therapy Designation, its Science and Technology Innovation Board (STAR Market) IPO application has entered the inquiry stage at the Shanghai Stock Exchange, and multiple brokerages have initiated coverage with Buy ratings and target prices significantly above current levels.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)